scispace - formally typeset
C

Christopher Dunham

Researcher at University of British Columbia

Publications -  67
Citations -  2344

Christopher Dunham is an academic researcher from University of British Columbia. The author has contributed to research in topics: Medulloblastoma & Medicine. The author has an hindex of 22, co-authored 62 publications receiving 1758 citations. Previous affiliations of Christopher Dunham include Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas

Ana Guerreiro Stucklin, +65 more
TL;DR: It is concluded that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies and revealing genetic alterations which may offer therapeutic opportunities.
Journal ArticleDOI

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors

Jonathon Torchia, +120 more
- 12 Dec 2016 - 
TL;DR: It is discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and it is suggested that these are promising therapies for this highly lethal ATRT subtype.
Journal ArticleDOI

Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas

TL;DR: Stratification of AOA, but not of pure AO, into grades 3 and 4 on the basis of necrosis is prognostically justified and is more powerful than the current approach.
Journal ArticleDOI

Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.

TL;DR: In conclusion, immunohistochemical evaluation of H3K27me3 global reduction is an economic, easily available and readily adaptable method for defining high-risk EPN_PFA from low-risk posterior fossa EPN-PFB tumors to inform prognosis and to enable the design of future clinical trials.
Journal ArticleDOI

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis

Vijay Ramaswamy, +123 more
TL;DR: The most impactful biomarker for posterior fossa ependymoma is molecular subgroup affiliation, independent of other demographic or treatment variables, with the survival rates being particularly poor for subtotally resected EPN_PFA, even with adjuvant radiation therapy.